Other NF2-related tumors
Showing 1 - 25 of >10,000
Vestibular Schwannoma, Neurofibromatosis Type 2 Trial in Beijing (Icotinib)
Completed
- Vestibular Schwannoma
- Neurofibromatosis Type 2
-
Beijing, Beijing, China
- +1 more
Sep 8, 2021
Neurofibromatosis Type 2, Neuroma, Acoustic Trial in Los Angeles (RAD001, everolimus)
Active, not recruiting
- Neurofibromatosis Type 2
- Neuroma, Acoustic
- RAD001, everolimus
-
Los Angeles, CaliforniaUniversity of California Los Angeles
Mar 2, 2022
HER2-expressing Advanced Solid Tumors Trial (SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor
Not yet recruiting
- HER2-expressing Advanced Solid Tumors
- SHR-A1811 combined with Pyrotinib.
- SHR-A1811 combined with other antitumor therapies
- (no location specified)
Aug 28, 2023
Tumor, Solid, Pancreatic Cancer Trial in Chapel Hill (Ulixertinib, Palbociclib)
Recruiting
- Tumor, Solid
- +2 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center
Nov 30, 2022
HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and
Not yet recruiting
- HER2+ Advanced Breast Cancer
- Other Solid Tumors
- ADCC-R-Epo-R T-cells + Trastuzumab
- +2 more
- (no location specified)
Aug 31, 2023
Colorectal Cancer, Solid Tumors Trial (SNDX-5613, Chemotherapy)
Not yet recruiting
- Colorectal Cancer
- Solid Tumors
- (no location specified)
Feb 15, 2023
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Defactinib
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Defactinib Hydrochloride
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 28, 2022
KRAS Mutation-Related Tumors, Metastatic Solid Tumor, Advanced Solid Tumor Trial in United States (TPX-0005, Trametinib)
Active, not recruiting
- KRAS Mutation-Related Tumors
- +2 more
-
Los Angeles, California
- +5 more
Nov 7, 2022
Head and Neck Squamous Cell Carcinoma Trial (HS-20093)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- (no location specified)
Aug 17, 2023
Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)
Not yet recruiting
- Advanced Solid Tumor
- +8 more
- BGB-43395
- +2 more
- (no location specified)
Nov 13, 2023
Called ROCURS, to Learn About COVID-19 Related Outcomes in
Active, not recruiting
- Malignant Solid Tumors
- +2 more
- Non-TKIs
- +3 more
-
Whippany, New JerseyBayer
Feb 2, 2023
Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma Trial in Singapore (FDG-PET, Galium-68 DOTATATE)
Recruiting
- Nasopharyngeal Cancer
- Epstein-Barr Virus Related Carcinoma
- FDG-PET
- Galium-68 DOTATATE
-
Singapore, SingaporeNational Cancer Centre Singapore
Oct 13, 2022
High-grade Glioma, Solid Tumor, Unspecified, Child Trial in Edison (2-OHOA)
Recruiting
- High-grade Glioma
- Solid Tumor, Unspecified, Child
-
Edison, New JerseyHackensack Meridian Health, Inc
Aug 16, 2022
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)
Not yet recruiting
- Locally Advanced Urothelial Carcinoma
- +3 more
- (no location specified)
Sep 15, 2022
Neuroendocrine Tumors, Carcinoid Tumor of GI System, Diarrhea Trial in Lexington (Amino Acid Based Medical Food/Drink)
Completed
- Neuroendocrine Tumors
- +3 more
- Amino Acid Based Medical Food/Drink
-
Lexington, KentuckyUniversity of Kentucky Markey Cancer Center
Nov 2, 2022
Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)
Active, not recruiting
- Advanced Breast Cancer
- +2 more
- Talazoparib Tosylate
-
Stanford, CaliforniaStanford University Hospitals and Clinics
Nov 16, 2022
Advanced or Metastatic Solid Tumors Trial in United States (MDK-703, Checkpoint Inhibitor, Immune)
Recruiting
- Advanced or Metastatic Solid Tumors
- MDK-703
- Checkpoint Inhibitor, Immune
-
Sarasota, Florida
- +4 more
Feb 10, 2023
Solid Tumor, KRAS Mutation-Related Tumors Trial in Washington (NEROFE, Doxorubicin)
Recruiting
- Solid Tumor
- KRAS Mutation-Related Tumors
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
Jan 23, 2023
Neuroblastoma, Neuroblastoma Recurrent, GD2-positive Solid Tumors Trial in Roma (GD2-CART01)
Recruiting
- Neuroblastoma
- +5 more
- GD2-CART01
-
Roma, ItalyOspedale Pediatrico Bambino Gesù
Mar 9, 2022